PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33569679-0 2021 Sensitive sandwich-type voltammetric immunosensor for breast cancer biomarker HER2 detection based on gold nanoparticles decorated Cu-MOF and Cu2ZnSnS4 NPs/Pt/g-C3N4 composite. Platinum 156-158 erb-b2 receptor tyrosine kinase 2 Homo sapiens 78-82 33932503-3 2021 PATIENTS AND METHODS: KATHERINE enrolled HER2-positive EBC patients with residual invasive disease in the breast/axilla at surgery after NACT containing a taxane (+-anthracycline, +-platinum) and trastuzumab (+-pertuzumab). Platinum 182-190 erb-b2 receptor tyrosine kinase 2 Homo sapiens 41-45 33916671-7 2021 Studies carried out on the SKOV-3 cell line with the use of a synthesized targeting bioconjugate (Au@Pt-PEG-trastuzumab) revealed a high affinity of this preparation to HER2+ cells, its internalization, its placement in the perinuclear area and partial intranuclear location. Platinum 101-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 169-173 32970266-2 2021 METHODS: The study includes patients with HER2(-) AGC treated with platin and fluoropyrimidine (PF) or with DPF in first line. Platinum 67-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 42-46 31815582-1 2020 PURPOSE: Platinum-based therapy is the standard of care in patients who have HER2-negative, advanced esophagogastric cancer (AEGC). Platinum 9-17 erb-b2 receptor tyrosine kinase 2 Homo sapiens 77-81 32984690-4 2020 In this study, we designed and synthesized platinum (Pt) nanocluster bionanoprobes with red emission (Ex/Em = 535/630 nm) for fluorescence imaging of HER2. Platinum 43-51 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-154 32984690-4 2020 In this study, we designed and synthesized platinum (Pt) nanocluster bionanoprobes with red emission (Ex/Em = 535/630 nm) for fluorescence imaging of HER2. Platinum 53-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 150-154 32750194-6 2020 To the best of our knowledge, this is the first platinum-based complex inhibiting HER2 expression containing no protein or peptide. Platinum 48-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 82-86 32735623-8 2020 PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Platinum 120-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 173-177 32235305-1 2020 Trastuzumab in combination with a platinum and fluorouracil is the treatment of choice for patients with advanced human epidermal growth factor receptor 2 (HER2) positive gastric cancer and gastroesophageal junction (GEJ) cancer. Platinum 34-42 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-154 31409079-9 2019 Patients treated in a neoadjuvant setting with platinum-based antineoplastic drugs had a 4.4x greater chance of achieving pCR than those not treated with platinum, assuming the same tumor phenotype (TNBC or SR+/HER2). Platinum 47-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 211-215 30909992-0 2019 [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung : Adenocarcinoma]. Platinum 98-106 erb-b2 receptor tyrosine kinase 2 Homo sapiens 25-29 30909992-3 2019 The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma. Platinum 81-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 120-124 30909992-3 2019 The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma. Platinum 81-89 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-140 30909992-13 2019 CONCLUSIONS: HER2-mutant lung adenocarcinoma patients with first-line pemetrexed combined with platinum chemotherapy have greater clinical benefit than HER2 wild-type patients. Platinum 95-103 erb-b2 receptor tyrosine kinase 2 Homo sapiens 13-17 30504425-1 2019 PURPOSE: Despite the clinical advantage of the combination of trastuzumab and platinum-based chemotherapy in HER2-amplified tumors, resistance will eventually develop. Platinum 78-86 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 28989055-0 2017 Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Platinum 92-100 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-33 30124494-1 2019 BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. Platinum 51-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 122-156 30124494-1 2019 BACKGROUND: Combination therapy with fluorouracil, platinum, and trastuzumab (Tmab) is the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, and there is currently no established second-line therapy. Platinum 51-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 158-162 30326862-3 2018 We aimed to evaluate whether PBBPs could have predictive value in HER2-positive ABC treated with pertuzumab and trastuzumab (PT) combined with eribulin (ERI) or nab-paclitaxel (Nab-PTX). Platinum 125-127 erb-b2 receptor tyrosine kinase 2 Homo sapiens 66-70 28944120-6 2017 Here, we describe the case of a 64-year-old man with Stage IIB (tumor size 2 to 5 cm with involvement of axillary lymph nodes), high-grade estrogen receptor, progesterone receptor, and HER2-positive invasive ductal carcinoma with a germline breast cancer susceptibility gene 1 (BRCA1) mutation who was treated in a neoadjuvant fashion with dual HER2 blockade and platinum-based chemotherapy regimen. Platinum 363-371 erb-b2 receptor tyrosine kinase 2 Homo sapiens 185-189 29254172-1 2017 Introduction: Trastuzumab in combination with platinum-based chemotherapy is the standard first-line regimen in HER2-positive advanced gastric cancer. Platinum 46-54 erb-b2 receptor tyrosine kinase 2 Homo sapiens 112-116 27044931-14 2016 CONCLUSION: Afatinib demonstrated significant activity in patients with platinum-refractory UC with HER2 or ERBB3 alterations. Platinum 72-80 erb-b2 receptor tyrosine kinase 2 Homo sapiens 100-104 26186063-3 2015 In this work, we described the design, synthesis, and characterization of conjugates combining trastuzumab with a platinum (IV) analog of oxaliplatin, in which the trastuzumab acted as an active targeting agent for HER2-positive cancer cells. Platinum 114-122 erb-b2 receptor tyrosine kinase 2 Homo sapiens 215-219 27016235-10 2016 Patients with HER2 overexpression (2/7, 28.6%) had germline HR mutations and were platinum-sensitive. Platinum 82-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 14-18 26693899-8 2016 Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy. Platinum 11-19 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 26693899-8 2016 Instead, a platinum score of 13 copy number regions, among other genes including MECOM, CCNE1 and ERBB2, correlated with platinum-free interval (PFI) after first-line therapy, whereas an increase of this score in recurrent tumours predicted the change in PFI during subsequent therapy. Platinum 121-129 erb-b2 receptor tyrosine kinase 2 Homo sapiens 98-103 26588239-3 2016 In the present study, we performed a retrospective investigation of the association between TOP2A, HER2 overexpression, and disease-free and overall survival in patients with endometrial cancer receiving taxane and platinum. Platinum 215-223 erb-b2 receptor tyrosine kinase 2 Homo sapiens 99-103 26099969-1 2015 PURPOSE: The use of trastuzumab, a monoclonal antibody targeting the HER2 protein, in combination with 5-fluorouracil/platinum-based chemotherapy improves survival in patients with HER2-positive advanced gastric cancer. Platinum 118-126 erb-b2 receptor tyrosine kinase 2 Homo sapiens 181-185 25467313-2 2015 Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates. Platinum 0-8 erb-b2 receptor tyrosine kinase 2 Homo sapiens 55-59 26211591-4 2015 Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery. Platinum 87-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 68-72 26211591-4 2015 Here we describe a nover conjugate comprising of Herceptin (an anti-HER2 antibody) and platinum drug via a cathepsin B cleavable dipetide for enhancing drug accumulation and HER2-positive cancer cell specific delivery. Platinum 87-95 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-178 25467313-8 2015 CONCLUSIONS: Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC. Platinum 55-63 erb-b2 receptor tyrosine kinase 2 Homo sapiens 115-119 23197882-4 2012 In patients with advanced or metastatic gastric/GOJ cancer systemic chemotherapy with fluoropyrimidine/platinum-based regimens (+/-human epidermal growth factor receptor-2 antibody) is the mainstay of treatment. Platinum 103-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 137-171 26359224-4 2015 For human epidermal growth factor receptors 2 (HER2) negative cancer, standard treatments are combinations of fluoropyrimidine and platinum with or without epirubicin or docetaxel in first-line therapy. Platinum 131-139 erb-b2 receptor tyrosine kinase 2 Homo sapiens 47-51 23680713-5 2013 The anti-HER-2 antibody, trastuzumab, when added to a chemotherapeutic regimen combining a fluoropyrimidine and platinum, provides a survival benefit for those patients with HER-2 overexpression and/or amplification. Platinum 112-120 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-14 25602630-7 2015 Patients with high-grade serous ovarian cancer and high HER2 levels had poor overall survival; however, better survival in the low HER2 patient subgroup treated with platinum/taxane-based therapy correlated positively with PRP4K expression (HR = 0.37 [95% CI 0.15-0.88]; p = 0.03). Platinum 166-174 erb-b2 receptor tyrosine kinase 2 Homo sapiens 131-135 21135055-0 2011 An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Platinum 85-93 erb-b2 receptor tyrosine kinase 2 Homo sapiens 116-120 22990650-7 2012 MDM2 (P=0.032) and ERBB2 (P=0.064) expression was increased in platinum-sensitive patients, and FGF1 (adjusted log-rank test P=0.006), FGFR2 (P=0.04) and PDRFRB expression (P=0.037) significantly inversely influenced progression-free survival. Platinum 63-71 erb-b2 receptor tyrosine kinase 2 Homo sapiens 19-24 22396490-7 2012 For example, low expression of the Xist gene correlated with cisplatin hypersensitivity in most tumors, and it also predicted long recurrence-free survival of HER2-negative, stage III breast cancer patients treated with intensive platinum-based chemotherapy. Platinum 230-238 erb-b2 receptor tyrosine kinase 2 Homo sapiens 159-163 21985855-1 2011 BACKGROUND: For patients with HER2-overexpressing gastric cancer, there is an improved prognosis with additional trastuzumab to chemotherapy with a platinum compound and a fluoropyrimidin in first-line therapy. Platinum 148-156 erb-b2 receptor tyrosine kinase 2 Homo sapiens 30-34 15545967-2 2004 We evaluated clinical significance of ERBB2 expression in relation to TP53 accumulation in ovarian carcinoma patients treated with platinum-based regimens. Platinum 131-139 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-43 19028616-4 2008 Moreover, platinum compounds have shown synergistic activity with trastuzumab, a monoclonal antibody against overexpressing HER2 breast cancer. Platinum 10-18 erb-b2 receptor tyrosine kinase 2 Homo sapiens 124-128 20417484-0 2010 Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Platinum 28-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 130-135 20417484-0 2010 Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Platinum 28-36 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-139 20417484-4 2010 High HER-2/neu expressors were more sensitive to platinum compounds, manifesting a 5.22-fold decrease in carboplatin-IC(50) (P = .005) and a 5.37-fold decrease in cisplatin-IC(50) (P = .02). Platinum 49-57 erb-b2 receptor tyrosine kinase 2 Homo sapiens 5-14 20417484-6 2010 CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors. Platinum 82-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-37 20417484-6 2010 CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors. Platinum 82-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 38-41 20417484-6 2010 CONCLUSION: USPC overexpressing HER-2/neu display greater in vitro sensitivity to platinum compounds when compared to low HER-2/neu expressors. Platinum 82-90 erb-b2 receptor tyrosine kinase 2 Homo sapiens 32-41 19258951-0 2009 Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Platinum 127-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 20-60 19258951-0 2009 Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Platinum 127-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 62-67 19258951-0 2009 Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. Platinum 127-135 erb-b2 receptor tyrosine kinase 2 Homo sapiens 69-72 19258951-2 2009 This exploratory analysis evaluates Her-2/neu as a prognostic factor in a large cohort of patients with advanced-stage ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy within a prospective randomized trial. Platinum 147-155 erb-b2 receptor tyrosine kinase 2 Homo sapiens 36-45 15865102-6 2005 Elevated HER-2 ECD concentration was related only to pT (p=0.0008), histological grade (p=0.0465), presence of comedonecrosis (p=0.0123) or comedo-type carcinoma (p=0.041) and was unrelated to the presence of an intraductal component. Platinum 53-55 erb-b2 receptor tyrosine kinase 2 Homo sapiens 9-14 15685824-0 2004 Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Platinum 51-59 erb-b2 receptor tyrosine kinase 2 Homo sapiens 94-98 11899413-1 2001 Interest in platinum compounds for the treatment of breast cancer has been reawakened because of preclinical studies indicating synergy of platinum salts with the monoclonal antibody trastuzumab in human breast cancer cell lines that overexpress HER2/neu. Platinum 12-20 erb-b2 receptor tyrosine kinase 2 Homo sapiens 246-250 14729645-8 2004 Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds. Platinum 68-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 216-222 14729645-8 2004 Among the parameters already known as related to the sensitivity to platinum compounds, we identified, in the complete set of 9400 genes, numerous significant relationships, such as the negative correlations between ERB-B2 and BCL-X(L) expressions and the cytotoxicity of the platinum compounds. Platinum 276-284 erb-b2 receptor tyrosine kinase 2 Homo sapiens 216-222 12694661-0 2003 Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy. Platinum 65-73 erb-b2 receptor tyrosine kinase 2 Homo sapiens 0-9 12694661-1 2003 OBJECTIVE: Our objective was to determine if the level of Her-2/neu expression in advanced ovarian cancer changed after platinum-based chemotherapy. Platinum 120-128 erb-b2 receptor tyrosine kinase 2 Homo sapiens 58-67 12694661-5 2003 After platinum chemotherapy, Her-2/neu expression changed from 0 to 1+ in 7 patients, from 1+ to 0 in 4 patients, 0 to 2+ in 1 patient, and 1+ to 2+ in 2 patients and no change was seen in 29 patients. Platinum 6-14 erb-b2 receptor tyrosine kinase 2 Homo sapiens 29-38 11899413-12 2001 Of greatest interest is the synergy between the platinum derivatives and the monoclonal antibody trastuzumab demonstrated in vitro in breast cancer cell lines overexpressing HER2/neu. Platinum 48-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 174-178 11899413-12 2001 Of greatest interest is the synergy between the platinum derivatives and the monoclonal antibody trastuzumab demonstrated in vitro in breast cancer cell lines overexpressing HER2/neu. Platinum 48-56 erb-b2 receptor tyrosine kinase 2 Homo sapiens 179-182 11899413-13 2001 Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu. Platinum 35-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 183-187 11899413-13 2001 Currently, several combinations of platinum compounds (either cisplatin or carboplatin) with docetaxel and trastuzumab are under clinical testing in patients with MBC who overexpress HER2/neu. Platinum 35-43 erb-b2 receptor tyrosine kinase 2 Homo sapiens 188-191 19780241-2 2004 Recent clinical studies, however, suggest that regimens of taxane/platinum/trastuzumab are effective option for first-line treatment of HER2-overexpressing metastatic disease, and that docetaxel/carboplatin is viable in first-line treatment of HER2-negative metastatic disease, as well as in neoadjuvant therapy of locally advanced breast cancer. Platinum 66-74 erb-b2 receptor tyrosine kinase 2 Homo sapiens 136-140 11899413-1 2001 Interest in platinum compounds for the treatment of breast cancer has been reawakened because of preclinical studies indicating synergy of platinum salts with the monoclonal antibody trastuzumab in human breast cancer cell lines that overexpress HER2/neu. Platinum 12-20 erb-b2 receptor tyrosine kinase 2 Homo sapiens 251-254 34933901-3 2022 Coupling whole exome sequencing, bulk RNA and single-cell transcriptomics from paired pre- and on-treatment samples in treatment naive HER2-positive and HER2-negative gastric cancer patients, we define features associated with response to platinum-based CTX. Platinum 239-247 erb-b2 receptor tyrosine kinase 2 Homo sapiens 135-139 9475194-7 1998 We conclude that there is a significant total dose-response effect of platin-based chemotherapy in ovarian cancer patients without overexpression of c-erbB-2 but not in patients with c-erbB-2 overexpression. Platinum 70-76 erb-b2 receptor tyrosine kinase 2 Homo sapiens 149-157 9383735-9 1997 Antioxidants, such as methionine, sodium thiosulfate, catalase, or platinum, prevented Met oxidation in rhuMAb HER2, presumably as free radicals or oxygen scavengers. Platinum 67-75 erb-b2 receptor tyrosine kinase 2 Homo sapiens 111-115 8652251-8 1995 Initially overexpressed in only a few tumours, the c-erbB-2 oncoprotein became overexpressed in 36% of platinum-resistant tumours; this modulation did not occur in platinum-sensitive tumours. Platinum 103-111 erb-b2 receptor tyrosine kinase 2 Homo sapiens 51-59 34933901-3 2022 Coupling whole exome sequencing, bulk RNA and single-cell transcriptomics from paired pre- and on-treatment samples in treatment naive HER2-positive and HER2-negative gastric cancer patients, we define features associated with response to platinum-based CTX. Platinum 239-247 erb-b2 receptor tyrosine kinase 2 Homo sapiens 153-157 35092538-6 2022 CONCLUSION: Our analyses suggest that 14% of ER+/Her2- patients may be HRD and therefore potentially eligible for treatments with HRD-directed therapies such as platinum agents and PARP inhibitors. Platinum 161-169 erb-b2 receptor tyrosine kinase 2 Homo sapiens 49-53 34420059-0 2022 Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. Platinum 139-147 erb-b2 receptor tyrosine kinase 2 Homo sapiens 67-71 34420059-1 2022 BACKGROUND: We aimed to evaluate the prognostic value of natural killer (NK) cell activity for patients with HER2 + advanced gastric cancer (AGC) treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. Platinum 187-195 erb-b2 receptor tyrosine kinase 2 Homo sapiens 109-113 34293698-0 2021 Platinum complexes inhibit HER-2 enriched and triple-negative breast cancer cells metabolism to suppress growth, stemness and migration by targeting PKM/LDHA and CCND1/BCL2/ATG3 signaling pathways. Platinum 0-8 erb-b2 receptor tyrosine kinase 2 Homo sapiens 27-32